Skip to main content

Table 4 Association between eNOS Haplotypes and PFS and OS

From: eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial

eNOS haplotypes

CT + B

CT

n

Median PFS (95% CI)

HR (95% CI)

P*

n

Median PFS (95% CI)

HR (95% CI)

P*

Haplo1/Haplo1

24

17.8 (8.1–22.3)

0.46 (0.27–0.78)

 

33

10.3 (8.0–15.0)

0.71 (0.46–1.10)

 

Other

90

9.6 (8.3–10.9)

1.00

0.004

86

9.0 (7.8–9.6)

1.00

0.123

Haplo2/Haplo2

15

13.1 (7.2–15.7)

0.82 (0.46–1.46)

 

16

9.9 (5.9–11.5)

1.44 (0.82–2.51)

 

Other

99

9.6 (8.3–11.3)

1.00

0.501

107

9.0 (8.3–10.2)

1.00

0.199

Haplo1/Haplo1 + Haplo2/Haplo2

39

15.0 (10.6–18.7)

0.48 (0.30–0.75)

 

49

10.3 (8.3–11.5)

0.88 (0.60–1.31)

 

Other

75

9.1 (7.4–10.1)

1.00

0.001

70

9.0 (7.2–9.6)

1.00

0.542

eNOS haplotypes

CT + B

CT

n

Median OS (95% CI)

HR (95% CI)

P*

n

Median OS (95% CI)

HR (95% CI)

P*

Haplo1/Haplo1

24

31.6 (19.3–nr)

0.46 (0.24–0.86)

 

33

23.2 (16.8–39.7)

0.80 (0.49–1.31)

 

Other

90

21.3 (15.9–25.2)

1.00

0.016

86

20.8 (18.2–24.5)

1.00

0.379

Haplo2/Haplo2

15

34.5 (13.1–42.9)

0.70 (0.37–1.31)

 

16

21.3 (14.4–26.4)

1.35 (0.73–2.50)

 

Other

99

21.3 (16.4–24.7)

1.00

0.260

107

21.6 (19.2–27.1)

1.00

0.331

Haplo1/Haplo1 + Haplo2/Haplo2

39

34.5 (23.4–38.4)

0.42 (0.25–0.72)

 

49

21.7 (18.8–29.6)

0.95 (0.61–1.48)

 

Other

75

20.5 (14.4–22.7)

1.00

0.002

70

20.8 (18.2–27.1)

1.00

0.829

  1. *Adjusted for CT (FOLFOX4/FOLFIRI), gender, age, KRAS status, tumor localization (rectum/colon).